Shanghai Securities News China Securities Network News -- According to Joincare, on March 20, Joincare Pharmaceutical Group Industry Co., Ltd. signed an exclusive licensing agreement with Bayer AG for the development, commercialization, and production of a small molecule inhibitor in China. This marks the first time Joincare has introduced an innovative drug pipeline in the respiratory field from a world-leading multinational company.
The small molecule compound involved is an innovative oral drug for chronic obstructive pulmonary disease (COPD). By inhibiting prolyl endopeptidase (PREP) activity, it effectively prevents the production of COPD inflammatory mediators. This unique mechanism of action is expected to bring significant benefits to COPD patients and may positively impact the overall progression of the disease.